| Predictors of response and relapse in a cohort of adults with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: a single-institution experience. | |
| | |
MedLine Citation:
|
PMID: 17207238 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) is a diagnosis of exclusion when a patient presents with the sine qua non findings of thrombocytopenia and microangiopathic hemolytic anemia without an identifiable cause. Although most patients respond to therapeutic plasma exchange (TPE), a significant number of patients relapse. The aim was to determine if clinical, laboratory, and/or treatment features could predict response and/or relapse. STUDY DESIGN AND METHODS: This study was a retrospective review of adults with TTP-HUS treated with TPE at our institution from January 1996 to February 2004. RESULTS: The study population consisted of 90 patients (69% female) with mean age of 45 years and mostly obese (65%). The majority of cases were considered idiopathic. Ten patients died (11%) from the disease before achieving a response, whereas 79 percent were considered responders. Obesity and severe anemia at presentation were predictors of response to TPE (p = 0.0126 and p = 0.0071, respectively). Among the responders, 28 percent relapsed in a median of 14 months. Male sex, severe thrombocytopenia (mean +/- SD, 13 x 10(9) +/- 8 x 10(9)/L), and higher lactate dehydrogenase pre-/posttreatment ratio were associated with relapse (p values of 0.0141, 0.0199, and 0.0407, respectively). ADAMTS-13 values were not obtained on enough number of patients to provide important data. CONCLUSION: Although patient and laboratory characteristics associated with response and relapse were identified, there was significant overlap between patient groups. Thus, our findings offer preliminary evidence and do not yet justify short- or long-term changes in the management of patients with TTP-HUS. |
| | |
Authors:
|
Hande H Tuncer; Robert A Oster; Shu T Huang; Marisa B Marques |
Related Documents
:
|
8900758 - Recombinant human erythropoietin treatment of anemic cancer patients. 19006118 - Impact of anemia on physical function and survival among patients with coronary artery ... 8237278 - Retrospective study on the influence of human parvovirus b19 infection among children w... 949188 - Primary hyperparathyroidism and anemia. 3388298 - Congenital deficiency of plasminogen and its relationship to venous thrombosis. 11399918 - Parathyroidectomy in chronic renal failure: short- and long-term results on parathyroid... |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural |
Journal Detail:
|
Title: Transfusion Volume: 47 ISSN: 0041-1132 ISO Abbreviation: Transfusion Publication Date: 2007 Jan |
Date Detail:
|
Created Date: 2007-01-08 Completed Date: 2007-02-07 Revised Date: 2007-12-03 |
Medline Journal Info:
|
Nlm Unique ID: 0417360 Medline TA: Transfusion Country: United States |
Other Details:
|
Languages: eng Pagination: 107-14 Citation Subset: IM |
Affiliation:
|
Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, USA. htuncer@tufts-nemc.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Anemia / complications, physiopathology Cohort Studies Female Hemolytic-Uremic Syndrome / blood, complications, therapy* Humans L-Lactate Dehydrogenase / blood Male Middle Aged Obesity / complications Plasma Exchange* Predictive Value of Tests Prognosis Purpura, Thrombotic Thrombocytopenic / blood, complications, therapy* Recurrence Retrospective Studies Severity of Illness Index Sex Factors Treatment Outcome |
| Grant Support | |
ID/Acronym/Agency:
|
M01 RR-00032/RR/NCRR NIH HHS |
| Chemical | |
Reg. No./Substance:
|
EC 1.1.1.27/L-Lactate Dehydrogenase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Monitoring survival and function of transfused platelets in Bernard-Soulier syndrome by flow cytomet...
Next Document: Outpatient high-dose melphalan in multiple myeloma patients.